Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome

Phase 4CompletedNCT00138528

Novartis55 enrolled

Overview

Other effects of fluvastatin are investigated in German patients with metabolic syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Metabolic Syndrome

Interventions

FluvastatinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent * Male and female patients, aged between 18 and 75 years * Metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) Exclusion Criteria: * History of heart failure * HIV positive * Stroke Other protocol defined inclusion and exclusion criteria may apply.

Locations (1)

Novartis

Nuremberg, Germany

Outcomes

Primary Outcomes

Change from baseline in circulating marker of inflammation (C-reactive protein) after 5 weeks

Secondary Outcomes

Change from baseline in low density lipoprotein cholesterol after 5 weeks

Change from baseline in non high density lipoprotein cholesterol after 5 weeks

Change from baseline in total cholesterol after 5 weeks

Change from baseline in high density lipoprotein cholesterol after 5 weeks

Change from baseline in oxidized low density lipoprotein cholesterol after 5 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.